News Release

HYDERABAD, INDIA (5 Nov 2026) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter and half year ended 30 Sep 2026. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 5 Nov 2026 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			6 months period ended		Year ended
	30-Sep-26	30-Jun-26	30-Sep-25	30-Sep-26	30-Sep-25	31-Mar-26
Revenue	*79.33*	*110.89*	*46.97*	*190.22*	*71.64*	*210.45*
R&D and Operational expenses	1,121.15	1,360.68	806.90	2,481.83	1,333.05	2,916.17
Depreciation and Amortisation	23.02	21.55	13.17	44.57	26.85	56.14
Finance cost	4.58	4.76	-	9.34	-	1.58
Total expenses	*1,148.75*	*1,387.00*	*820.07*	*2,535.75*	*1,359.91*	*2,973.89*
Exceptional items (insurance claim received)	-	-	-	-	-	-
Tax	-	-	-	-	-	-
Profit/(Loss) After Tax for the period/year	*(1,069.42)*	*(1,276.10)*	*(773.10)*	*(2,345.52)*	*(1,288.27)*	*(2,763.44)*
Other comprehensive income	(2.34)	(0.36)	0.85	(2.70)	0.34	(11.84)
Total comprehensive income	*(1,071.77)*	*(1,276.46)*	*(772.25)*	*(2,348.23)*	*(1,287.93)*	*(2,775.28)*
Paid up equity capital	282.56	263.99	227.47	282.56	227.47	263.72
Earnings per share of Rs.1 each (EPS)	*(3.77)*	*(4.84)*	*(3.48)*	*(8.61)*	*(5.80)*	*(12.13)*

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Completed enrollment milestone in Global Phase 3 Trial for Agitation in Alzheimer's Dementia. The last patient last visit will be in quarter 1, 2027 calendar year enabling progression towards database lock and reporting of topline data potentially in Q2 - 2027 calendar year.
- SUVN-G3031 (Samelisant) – Global Phase-3 clinical study to confirm efficacy and safety of Samelisant in narcolepsy is in progress.
- SUVN-911 (Ropanicant) – Phase 2B clinical study in USA is completed with successful outcome. Targeting for Global Phase -3 program initiation during Q2-2027 calendar year.
- SUVN-D4010 (Usmarapride) – Phase-2 Proof of Concept (PoC) Study for Cognitive Dysfunction initiated during October 2026.
- SUVN-I6107 – Phase 1 study for establishing safety and pharmacokinetics completed and Phase 2 enabling toxicological studies are underway.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued in growth of revenue that may make our products/services offerings less competitive.